Nau mai, haere mai ki a Māori Health Review.
We aim to bring you top Māori and indigenous health research from Aotearoa and internationally.
Ngā mihi nui ki Manatu Hauora Māori for sponsoring this review, which comes to you every two months.
Ko te manu e kai i te miro nōna te ngahere, Ko te manu kai i te mātauranga, nōna te ao.
Ngā mihi
Matire
Dr Matire Harwood
matire@maorihealthreview.co.nz
Using New Zealand death registration and population data from 2013 through 2015, these researchers assessed life expectancy differentials associated with potentially avoidable causes of death within Māori and Pacific populations when compared to the non-Māori/non-Pacific population. As the study researchers explain, avoidable mortality can be used as a measure of how effectively healthcare, health and social policy are contributing to population health and health equity, by how many premature deaths occur from certain conditions and in the presence of timely, effective and equitable healthcare or other appropriate interventions. In each of the three target study populations, much higher proportions of all deaths were attributed to potentially avoidable causes of death among Māori (53.0%) and Pacific peoples (47.3%) than among non-Māori/non- Pacific populations (23.2%). Conditions considered to be both preventable and amenable made the greatest contribution to the life expectancy differentials within both Māori and Pacific groups, compared with non-Māori/ non-Pacific. Within Māori males and females, trachea, bronchus and lung cancers accounted for 0.8 and 0.9 years of the life expectancy differential, respectively. Avoidable injuries including suicide contributed as much as 1.0 year to the differential in Māori males. Coronary disease, diabetes and cerebrovascular disease were large contributors to the differential in both Pacific males and females.
Using EMR data for 375 patients registered as of 1 November 2017 with a Dunedin free ‘third sector’ primary healthcare clinic, these researchers sought to determine the prevalence of multimorbidity and multiple social disadvantage in relation to age, gender, deprivation and ethnicity. Multimorbidity affected around four-fifths (76.5%) of the cohort and half (49.9%) suffered from long-term physical and mental health comorbidities. Across all ethnicities and deprivation quintiles, the researchers found a high level of multimorbidity that increased with age. Of the 10 most prevalent long-term conditions, 7 were mental health conditions. Over half of the cohort (54.7%) had ≥1 multiple social disadvantage domain recorded.
These researchers analysed nationally linked data for all publicly funded health expenditure (including hospitalisation, outpatient, pharmaceutical, laboratory testing, and primary care) on 6 noncommunicable diseases (NCDs) listed as cancer, CVD, diabetes, musculoskeletal, neurological, and chronic lung, liver, or kidney disease, for New Zealand adults between 1 July 2007 and 30 June 2014. The data yielded 18.9 million person-years and a total health expenditure of $US26.4 billion ($US calculated in 2016). The analysis compared the costs of having ≥2 NCDs versus those expected from the independent costs of each NCD. It also disaggregated total health spending by NCDs across age and by sex. Around two-thirds (59%) of health expenditure was on NCDs and nearly one-quarter (23.8%) of all health expenditure on chronic NCDs was explained by costs relating to ≥2 diseases (i.e. costs due to comorbid conditions, exceeding the sum of having the diseases separately). Excess comorbidity costs for patients with 2 diseases were higher for younger-aged versus for older-aged patients; e.g. excess expenditure for 45–49-year-old males with CVD and chronic lung, liver, or kidney disease was 10 times higher than for 75–79-year-old males and 6 times higher for females. The remaining three-quarters of health expenditure was broken down as follows across the 6 NCDs (as though they were the only disease to affect a person): heart disease and stroke, 18.7%; musculoskeletal, 16.2%; neurological, 14.4%; cancer, 14.1%; chronic lung, liver, or kidney disease, 7.4%; and diabetes, 5.5%.
This study was designed to determine mediators of urate responses to a fructose load in a cohort of New Zealanders categorised by ethnicity: Māori (n=25), Pacific (n=26) and New Zealand European (n=25). Blood samples were obtained from each participant after consumption of a 64 g fructose/16 g glucose solution. The bloods were analysed for changes from baseline in lipids, glucose, insulin and C‐reactive protein. In analyses accounting for age and gender, glucose and insulin responses were significantly higher among people with higher BMI compared with those with lower BMI (p<0.01 for both comparisons). Whereas glucose levels were similar among people of Māori or Pacific ethnicity and those of New Zealand European ethnicity (p=0.077), Māori and Pasifika had significantly higher insulin responses (p=0.0005), which remained after additional BMI-adjusted analyses (p=0.001). Sugar‐sweetened beverage (SSB) intake was higher in the Māori and Pacific cohort than among New Zealand Europeans (median 1.0 vs 0.0 SSB/day; p=0.002).
New Zealand introduced pneumococcal conjugate vaccine (PCV)7 in June 2008, PCV10 in 2011, and PCV13 in 2014. In order to evaluate the impact of the PCV vaccination programme on hospitalisations for infectious disease, these researchers collated and analysed annual hospital admissions for invasive pneumococcal disease (IPD), all-cause pneumonia, and all-cause otitis media (OM) for New Zealand children aged <6 years between 2006 and 2015 by age group, ethnicity, geographical area, and socioeconomic deprivation. During the 10-year study period, 640 children were hospitalised for IPD, 26,589 for all-cause pneumonia and 44,545 for OM; hospitalisations for each disease fell by 73%, 8% and 25%, respectively, between 2006 and 2015. Although the hospitalisation rates for all diseases were highest among Māori and Pacific children, the rates fell by a greater extent among these children as compared with declines in hospitalisations among other ethnic groups. Similarly, the declines in hospitalisations fell disproportionately among children from areas of higher socioeconomic deprivation compared with those from less socioeconomically deprived areas.
This analysis retrospectively reviewed the data from all patients admitted with cardiac complications of thyrotoxicosis to a single New Zealand hospital between 1 January 2005 and 31 December 2012. Of 72 patients who were identified as being admitted for a cardiac complication of thyrotoxicosis, 32 were admitted because of dysrhythmia, 12 had ischaemia, 11 were in cardiac failure and 17 had mixed cardiac disease. Thyrotoxicosis was most commonly caused by Graves’ disease (n=25) and amiodarone (n=19). The cohort was over-represented by Māori (36.1% vs 16.8% of all cardiac admissions over the same period) and Māori were more likely to present with cardiac failure than non-Māori (57.7% vs 26.1%; p=0.008).
Using a qualitative and Kaupapa Māori methodology, these researchers interviewed 10 women with type 2 diabetes living in a rural community in Northland (an area marked by high social deprivation), who had experienced gestational diabetes mellitus (GDM) during pregnancy. Analyses of the narratives revealed that intergenerational experiences informed the women’s perception of GDM as an inevitable heritable illness, described as a condition that “just runs in the family”. Their lives were complicated by the cumulative effects of deprivation and living with GDM, and by their perceptions of powerlessness and mental health deterioration. Accounts of missed opportunities for appropriate diagnostic testing, treatment and health promotion programmes for GDM meant that the women and their offspring faced ongoing health consequences. When women developed positive relationships with healthcare providers, GDM was managed better within healthcare services and by the women themselves.
Using data from 14,043 adults with prediabetes enrolled in a primary health organisation in the upper North Island of New Zealand, these researchers examined the incidence of type 2 diabetes and sought to determine those factors that protect against this progression. After their first diagnosis of prediabetes (HbA1c ranging from 5.9–6.6% [41–49 mmol/mol]) between 2009 and 2017, the study participants were followed-up for type 2 diabetes incidence. The cumulative incidence of diabetes was 5.0% after 3 years. In Cox regression analyses adjusted for potential confounding, rates of progression were faster in younger adults, men, people with higher HbA1c, greater BMI and in those who were diagnosed more recently. Progression was slower among those treated with metformin and among those speaking te reo (New Zealand’s Indigenous language). Higher HbA1c at baseline was associated with higher progression rates for Māori and Pasifika.
This article describes a project that has been designed to integrate an Indigenous community of kaumātua with community health researchers and academic researchers working with 2 advisory boards in New Zealand, highlighting the potential of kaumātua (elders) by asserting mana motuhake (autonomy, identity and self-actualisation). Grounded in Kaupapa Māori principles and community-based participatory research, the project emphasises a strengths-based approach. It will follow a ‘tuakana-teina’ (older sibling/younger sibling) peer-educator model, enabling kaumātua to work with other kaumātua in relation to health and wellbeing. Thus, this project will seek to develop the capacity of kaumātua as peer educators and positively impact upon their sense of purpose, health and wellbeing, as well as endeavour to enhance social and health outcomes for kaumātua receiving the intervention. Findings over time are expected to provide an evidence base for the valuing of kaumātua knowledge that can be used to create contextually-based, culturally safe, age-friendly environments that facilitate engagement and participation by kaumātua for kaumātua.
Outcomes are reported from research that explored Māori and Pacific family experiences of recurrences of rheumatic fever, in an attempt to identify and understand barriers for families accessing secondary prophylaxis and ongoing management of rheumatic fever to inform health service improvements. The research employed Kaupapa Māori, Talanga and Kakala Pacific qualitative methodologies. Data were collected through 38 interviews conducted with 80 Māori and Pacific patients who had recurrences of rheumatic fever or unexpected rheumatic heart disease and their families, as well as 9 individual interviews and 6 focus group interviews with 33 health providers working in rheumatic fever contexts throughout 7 geographic regions. Thematic analysis of the data identified a consistent mismatch between the approach taken by rheumatic fever health services and what is needed by the population looked after by those services. The 3 main areas of service mismatch identified were model of delivery, interpersonal approaches to care and adolescent care.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Tēnā koutou katoa Nau mai, haere mai ki a Arotake Hauora Māori. We aim to
Tēnā koutou katoa Nau mai, haere mai ki a Arotake Hauora Māori. We aim to
Tēnā koutou katoa Nau mai, haere mai ki a Arotake Hauora Māori. We aim to
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.
